[go: up one dir, main page]

PE20030930A1 - Derivados de tiazol como antagonistas del receptor npy - Google Patents

Derivados de tiazol como antagonistas del receptor npy

Info

Publication number
PE20030930A1
PE20030930A1 PE2003000182A PE2003000182A PE20030930A1 PE 20030930 A1 PE20030930 A1 PE 20030930A1 PE 2003000182 A PE2003000182 A PE 2003000182A PE 2003000182 A PE2003000182 A PE 2003000182A PE 20030930 A1 PE20030930 A1 PE 20030930A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
alkyl
methyl
antagonists
thazol
Prior art date
Application number
PE2003000182A
Other languages
English (en)
Inventor
Patrizio Mattei
Werner Neidhart
Sven Taylor
Philippe Pflieger
Matthias Heinrich Nettekoven
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20030930A1 publication Critical patent/PE20030930A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A DERIVADOS DE TIAZOL DE FORMULA I DONDE R1 ES ARILO, HETEROARILO; R2 ES H, ALQUILO, CICLOALQUILO; R3 ES H, ALQUILO, CICLOALQUILO; R4 ES H, ALQUILO, CICLOALQUILO; R5 ES ALQUILO, CICLOALQUILO, ARILO, HETEROARILO; R6 ES H, ALQUILO, CICLOALQUILO; A ES -C(O)-, -S(O)2, -N(R6)-C(O)-, ENTRE OTROS. SON COMPUESTOS PREFERIDOS {3-[5-(2-METIL-BENZOIL)-TIAZOL-2-ILAMINO]-PROPIL}-AMIDA DEL ACIDO TIOFENO-2-SULFONICO, 2-METOXI-5-METIL-N-{3-[5-(2-METIL-BENZOIL)-TIAZOL-2-ILAMINO]-PROPIL}-BENCENOSULFONAMIDA, 2-CLORO-N-{3-[5-(2-METIL-BENZOIL)-TIAZOL-2-ILAMINO]-PROPIL}-5-TRIFLUOROMETIL-BENCENOSULFONAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON ANTAGONISTAS DEL RECEPTOR DE NEUROPEPTIDO Y (NPY) Y SON UTILES PARA EL TRATAMIENTO DE ARTRITIS, ENFERMEDADES CARDIOVASCULARES, DIABETES
PE2003000182A 2002-02-28 2003-02-25 Derivados de tiazol como antagonistas del receptor npy PE20030930A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02004296 2002-02-28

Publications (1)

Publication Number Publication Date
PE20030930A1 true PE20030930A1 (es) 2003-11-08

Family

ID=27763338

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000182A PE20030930A1 (es) 2002-02-28 2003-02-25 Derivados de tiazol como antagonistas del receptor npy

Country Status (21)

Country Link
US (1) US6686381B2 (es)
EP (1) EP1480976B1 (es)
JP (1) JP2005526732A (es)
KR (1) KR100611854B1 (es)
CN (1) CN100363362C (es)
AR (1) AR038704A1 (es)
AT (1) ATE373654T1 (es)
AU (1) AU2003210305B2 (es)
BR (1) BR0308108A (es)
CA (1) CA2475299A1 (es)
DE (1) DE60316411T2 (es)
ES (1) ES2292992T3 (es)
GT (1) GT200300045A (es)
MX (1) MXPA04008379A (es)
PA (1) PA8567301A1 (es)
PE (1) PE20030930A1 (es)
PL (1) PL372463A1 (es)
RU (1) RU2004129285A (es)
TW (1) TW200403995A (es)
UY (1) UY27689A1 (es)
WO (1) WO2003072577A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
BRPI0413458A (pt) 2003-08-12 2006-10-17 Hoffmann La Roche compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
JP2007501823A (ja) 2003-08-12 2007-02-01 エフ．ホフマン−ラ　ロシュ　アーゲー ２−アミノ−５−ベンゾイルチアゾールなるｎｐｙアンタゴニスト
DE602004011394T2 (de) * 2003-12-08 2009-01-08 F. Hoffmann-La Roche Ag Thiazolderivate
US7820704B2 (en) * 2004-04-20 2010-10-26 Transtech Pharma, Inc. Substituted heteroaryl derivatives, compositions, and methods of use
FR2884516B1 (fr) * 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
WO2007084391A2 (en) * 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
WO2010098298A1 (ja) * 2009-02-27 2010-09-02 塩野義製薬株式会社 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP7523351B2 (ja) 2018-01-31 2024-07-26 デシフェラ・ファーマシューティカルズ，エルエルシー 肥満細胞症の治療のための併用療法
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ，エルエルシー 消化管間質腫瘍の治療のための併用療法
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
NZ789199A (en) 2019-12-30 2025-07-25 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
AUPN163795A0 (en) 1995-03-10 1995-04-06 DIPNALL, David A device for extracting energy from moving water particles
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DE19824175A1 (de) * 1998-05-29 1999-12-02 Novartis Ag Amino-azol-Verbindungen
TR200100471T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
AU759388B2 (en) 1998-08-14 2003-04-10 Cheplapharm Arzneimittel Gmbh Pharmaceutical compositions containing lipase inhibitors and chitosan
US20010039275A1 (en) * 2000-02-04 2001-11-08 Bowler Andrew Neil Use of 2,4-diaminothiazole derivatives
AU2001246494A1 (en) * 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
EP1417188A1 (en) * 2001-08-03 2004-05-12 Novo Nordisk A/S Novel 2,4-diaminothiazole derivatives

Also Published As

Publication number Publication date
US6686381B2 (en) 2004-02-03
GT200300045A (es) 2003-09-23
MXPA04008379A (es) 2004-11-26
PA8567301A1 (es) 2004-02-07
RU2004129285A (ru) 2005-10-27
CN100363362C (zh) 2008-01-23
AU2003210305B2 (en) 2006-07-06
TW200403995A (en) 2004-03-16
CN1639158A (zh) 2005-07-13
KR100611854B1 (ko) 2006-08-11
WO2003072577A1 (en) 2003-09-04
EP1480976B1 (en) 2007-09-19
DE60316411T2 (de) 2008-06-12
CA2475299A1 (en) 2003-09-04
PL372463A1 (en) 2005-07-25
DE60316411D1 (de) 2007-10-31
BR0308108A (pt) 2004-12-07
UY27689A1 (es) 2003-08-29
US20030225141A1 (en) 2003-12-04
ATE373654T1 (de) 2007-10-15
AR038704A1 (es) 2005-01-26
AU2003210305A1 (en) 2003-09-09
KR20040094735A (ko) 2004-11-10
EP1480976A1 (en) 2004-12-01
ES2292992T3 (es) 2008-03-16
JP2005526732A (ja) 2005-09-08

Similar Documents

Publication Publication Date Title
PE20030930A1 (es) Derivados de tiazol como antagonistas del receptor npy
PE20050121A1 (es) Acidos tienil-hidroxamicos, sustituidos referidos a la actividad enzimatica de la histona desacetilasa
ES2524045T3 (es) Nuevas amidas y tioamidas heteroaromáticas como plaguicidas
KR100561988B1 (ko) 신규 화합물
EP0316723B1 (en) 3-[4(1-Substituted-4-piperazinyl)butyl]-4-thiazolidinones a process for their preparation and their use as medicaments
AU2631401A (en) Novel compounds and compositions as protease inhibitors
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
CO5690638A2 (es) Nuevos compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos; proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20051159A1 (es) Derivados de heteroarilaminopirazol como estimulantes de la produccion de insulina
NZ582555A (en) Sulfonamides as trpm8 modulators
KR20090110851A (ko) 키나제 저해제로서 2-아미노티아졸 화합물의 합성 공정
PE20081836A1 (es) Derivados de piperidina como inhibidores de la sintasa de acido graso
PE20040190A1 (es) Tiazoles y oxazoles sustituidos que modulan la actividad de ppar
AR035111A1 (es) Procedimiento para preparar un compuesto de pirimidinona
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20060727A1 (es) Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
PE20021158A1 (es) Derivados de sulfonamida como antagonistas del receptor de bradiquinina
PT2248809E (pt) (3-[2-(benzo[b]tiofen-5-il)-etoxi]-propanoatos de alquilo a título de intermediários na produção de derivados de azetidin-3-ol
PE20020603A1 (es) Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy)
PE20081683A1 (es) Nuevos derivados de sulfonamida
PE20050133A1 (es) Piperazinas sustituidas heterociclicas
US20040127426A1 (en) Peptidic compounds as cysteine protease inhibitors
PE20061446A1 (es) Compuestos de bencimidazol-carboxamida como agonistas de receptores 5-ht4
AR040123A1 (es) Compuestos tiofeno, antihelminticos e insecticidas

Legal Events

Date Code Title Description
FD Application declared void or lapsed